Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease

Journal of Virology

Volumn 85, Issue 13, 2011, Pages 6106-6116

  Romano, Keith P ^a   Laine, Jennifer M ^a   Deveau, Laura M ^a   Cao, Hong ^a   Massi, Francesca ^a   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 4A PROTEIN; 4A4B PROTEIN; 5A5B PROTEIN; MAVS PROTEIN; NS3/4A PROTEASE; PROLINE; PROTEINASE; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; CARRIER PROTEIN; MEMBRANE PROTEIN; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; POLYPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRIM PROTEIN, HUMAN; VIRUS PROTEIN; VISA PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME CONFORMATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HEPATITIS C VIRUS; HOST CELL; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PROCESSING; STATIC ELECTRICITY; VIRUS CELL INTERACTION; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; ENZYME ACTIVE SITE; GENETICS; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN CONFORMATION;

HEPATITIS C VIRUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARRIER PROTEINS; CATALYTIC DOMAIN; CRYSTALLIZATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE PROTEINS; MODELS, MOLECULAR; POLYPROTEINS; PROTEIN CONFORMATION; STATIC ELECTRICITY; SUBSTRATE SPECIFICITY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80052073390     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00377-11     Document Type: Article

References (37)

1. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732-738.
2. Bartenschlager, R., L. Ahlborn-Laake, J. Mous, and H. Jacobsen. 1994. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J. Virol. 68:5045-5055.
3. Bode, W., and R. Huber. 1978. Crystal structure analysis and refinement of two variants of trigonal trypsinogen: trigonal trypsin and PEG (polyethylene glycol) trypsinogen and their comparison with orthorhombic trypsin and trigonal trypsinogen. FEBS Lett. 90:265-269.
4. Brunger, A. T. 1992. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355:472-475.
5. Carter, P., and J. A. Wells. 1988. Dissecting the catalytic triad of a serine protease. Nature 332:564-568.
6. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 50:760-763.
7. Davis, I. W., et al. 2007. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35:W375-W383.
8. Delaglio, F., et al. 1995. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6:277-293.
9. DeLano, W. L. 2008. The PyMOL molecular graphics system. DeLano Scientific LLC, San Carlos, CA.
10. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
11. Ferreon, J. C., A. C. Ferreon, K. Li, and S. M. Lemon. 2005. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J. Biol. Chem. 280:20483-20492.
12. Foy, E., et al. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. U. S. A. 102:2986-2991.
13. Foy, E., et al. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300:1145-1148.
14. Gallinari, P., et al. 1998. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J. Virol. 72:6758-6769.
15. Goddard, T. D., and D. G. Kneller. SPARKY 3. University of California, San Francisco, CA.
16. He, Y., et al. 2008. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob. Agents Chemother. 52:1101-1110.
17. Kieffer, T. L., et al. 2007. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631-639.
18. Krishnan, R., J. E. Sadler, and A. Tulinsky. 2000. Structure of the Ser195Ala mutant of human alpha-thrombin complexed with fibrinopeptide A(7-16): evidence for residual catalytic activity. Acta Crystallogr. D Biol. Crystallogr. 56:406-410.
19. Krissinel, E., and K. Henrick. 2007. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372:774-797.
20. Lenz, O., et al. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54: 1878-1887.
21. Li, K., et al. 2005. Immune evasion by hepatitis C virus NS3/4A proteasemediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U. S. A. 102:2992-2997.
22. Lin, C., B. M. Pragai, A. Grakoui, J. Xu, and C. M. Rice. 1994. Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. J. Virol. 68:8147-8157.
23. Major, M. E., and S. M. Feinstone. 1997. The molecular virology of hepatitis C. Hepatology 25:1527-1538.
24. McCoy, A. J., et al. 2007. Phaser crystallographic software. J. Appl. Crystallogr. 40:658-674.
25. Morris, R. J., A. Perrakis, and V. S. Lamzin. 2002. ARP/wARP's modelbuilding algorithms. I. The main chain. Acta Crystallogr. D Biol. Crystallogr. 58:968-975.
26. Nalam, M. N., et al. 2010. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 84:5368-5378.
27. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
28. Prabu-Jeyabalan, M., E. A. Nalivaika, K. Romano, and C. A. Schiffer. 2006. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J. Virol. 80:3607-3616.
29. Romano, K. P., A. Ali, W. E. Royer, and C. A. Schiffer. 2010. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. U. S. A.
30. Sarrazin, C., et al. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132:1270-1278.
31. Steinkuhler, C., et al. 1998. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37:8899-8905.
32. Tong, X., et al. 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 77:177-185.
33. WHO. 8 February 2010, posting date. Vaccine research: hepatitis C. http: //www.who.int/csr/disease/hepatitis.
34. Wittekind, M., S. Weinheirner, Y. Zhang, and V. Goldfarb. August 2002. Modified forms of hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease:inhibitor complexes. U.S. patent 6,333,186.
35. Yao, N., P. Reichert, S. S. Taremi, W. W. Prosise, and P. C. Weber. 1999. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7:1353- 1363.
36. Yi, M., Y. Ma, J. Yates, and S. M. Lemon. 2009. Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation. PLoS Pathog. 5:e1000403.
37. Yoneyama, M., et al. 2005. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175:2851-2858.